The novel myosin activator, danicamtiv alters both systolic and diastolic functions in vitro and in vivo

被引：0
|
作者：
Raduly, A. [1 ]
Sarkany, F. [1 ]
Papp, Z. [1 ]
Toth, A. [1 ]
Csanadi, Z. [2 ]
Edes, I. [2 ]
Kovacs, M. [1 ]
Juhasz, B. [3 ]
Priksz, D. [3 ]
Borbely, A. [2 ]
机构：
[1] Univ Debrecen, Div Clin Physiol, Dept Cardiol, Fac Med, Debrecen, Hungary
[2] Univ Debrecen, Dept Cardiol, Fac Med, Debrecen, Hungary
[3] Univ Debrecen, Dept Pharmacol & Pharmacotherapy, Fac Med, Debrecen, Hungary
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2024年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：630 / 631
页数：2
相关论文
共 50 条
  • [1] The Novel Cardiac Myosin Activator Danicamtiv Improves Cardiac Systolic Function at the Expense of Diastolic Dysfunction In Vitro and In Vivo: Implications for Clinical Applications
    Raduly, Arnold Peter
    Sarkany, Fruzsina
    Kovacs, Mate Balazs
    Bernat, Brigitta
    Juhasz, Bela
    Szilvassy, Zoltan
    Porszasz, Robert
    Horvath, Balazs
    Szentandrassy, Norbert
    Nanasi, Peter
    Csanadi, Zoltan
    Edes, Istvan
    Toth, Attila
    Papp, Zoltan
    Priksz, Daniel
    Borbely, Attila
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (01)
  • [2] Preclinical in vitro and in vivo pharmacokinetic properties of danicamtiv, a new targeted myosin activator for the treatment of dilated cardiomyopathy
    Grillo, Mark P.
    Markova, Svetlana
    Evanchik, Marc
    Trellu, Marc
    Moliner, Patricia
    Brun, Priscilla
    Perreard-Dumaine, Anne
    Vicat, Pascale
    Driscoll, James P.
    Carlson, Tim J.
    XENOBIOTICA, 2021, 51 (02) : 222 - 238
  • [3] Cardiac muscle activation; the role of length dependent activation and the novel myosin activator danicamtiv
    Bell, K.
    Anto, A. R.
    Anderson, R. L.
    Del Rio, C. L.
    Henze, M.
    EUROPEAN HEART JOURNAL, 2020, 41 : 3681 - 3681
  • [4] Danicamtiv (MYK-491) a novel small-molecule cardiac activator: in vitro/in vivo evidence for overall myocardial inotropy
    Del Rio, C. L. Carlos Luis
    Bell, K.
    Anto, A.
    Gong, H.
    Henze, M.
    Roof, S. R.
    Ma, W.
    Sa, N.
    Gollapudi, S.
    Nag, S.
    Fernandes, S.
    Anderson, R. L.
    Irving, T.
    Mcdowell, R.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 3 - 4
  • [5] Cardiac Myosin Activator Omecamtiv Mecarbil: Novel Treatment for Systolic Heart Failure
    Mack, Maat
    Frishman, William H.
    CARDIOLOGY IN REVIEW, 2024, 32 (04) : 378 - 383
  • [6] The unconventional myosin MYR 5 functions as a rhoGAP in vitro and in vivo
    Muller, RT
    Honnert, U
    Reinhard, J
    Bahler, M
    MOLECULAR BIOLOGY OF THE CELL, 1996, 7 : 2166 - 2166
  • [7] In vitro and in vivo characterization of CK-1827452, a selective cardiac myosin activator
    Anderson, Robert L.
    Sueoka, Sandra H.
    Lee, Kenneth H.
    Rodriguez, Hector M.
    Kawas, Raja F.
    Godinez, Guillermo
    Morgan, Bradley P.
    Sakowicz, Roman
    Morgans, David J.
    Malik, Fady
    Elias, Kathleen A.
    JOURNAL OF CARDIAC FAILURE, 2006, 12 (06) : S86 - S86
  • [8] Akt alters apoptotic responses to tamoxifen both in vitro and in vivo.
    Russell, DH
    Donzis, EJ
    Middleton, AK
    Friedrichs, WE
    Silva, JM
    Roth, RA
    DeGraffenried, LA
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S57 - S57
  • [9] Both systolic and diastolic functions are impaired in critically ill patients with community-acquired sepsis
    S Hettwer
    M Schürmann
    J Wilhelm
    H Ebelt
    K Werdan
    Critical Care, 14 (Suppl 1):
  • [10] MYK-491, a Novel Small-Molecule Cardiac Myosin Activator Increases Cardiac Systolic Function and Preserves Mechanical Efficiency: Pre-Clinical in vivo and in vitro Evidence
    Fernandes, Sarah
    Oikonomopoulos, Angelos
    Jimenez-MacInnes, Sarah K.
    Aschar-Sobbi, Roozbeh
    Henze, Marcus
    Sumandea, Marius
    Gan, Qing-Fen
    Anderson, Robert L.
    del Rio, Carlos L.
    CIRCULATION, 2019, 140
12345